Perazone

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Perazone

Property Description
Active Ingredient Dexamethasone
Pharmacological Class Glucocorticoid (Corticosteroid)
Form Tablet, Solution, Injectable Suspension
General Purpose Suppression of inflammation and immune response
Origin Synthetic Adrenocortical Steroid

Perazone is the designated trade name for a medicine containing the active pharmaceutical ingredient Dexamethasone, a highly potent synthetic corticosteroid used to manage severe inflammatory and immune-related conditions. The drug is classified within the glucocorticoid pharmacological class.


The Identity and Classification of Perazone

The core identity of Perazone is defined by its active compound, Dexamethasone, which is a chemically manufactured, fluorinated steroid designed to mimic and amplify the effects of cortisol, a hormone naturally produced by the adrenal glands. Dexamethasone is clinically recognized for its exceptional potency and is an effective synthetic adrenocortical steroid. This powerful glucocorticoid function gives it a broad capability to influence metabolic and immune responses, distinguishing it as a long-acting compound often preferred when sustained anti-inflammatory action is required.


Composition and Physical Forms

Perazone is a single active ingredient product based entirely on Dexamethasone, which is formulated into various pharmaceutical preparations. Dexamethasone is available in diverse dosage forms necessary for clinical flexibility, including the most common tablet for oral intake, elixir or oral concentrate, and specialized injectable solution or suspension for parenteral administration. This variety ensures appropriate delivery, allowing for both systemic treatment and localized applications.


General Therapeutic Role of the Dexamethasone Compound

The general purpose of the Dexamethasone compound is to quickly and effectively suppress the body’s excessive response to inflammation and allergy. It achieves this by acting as a powerful Immunosuppressive Agent and Anti-Inflammatory Agent, which reduces the number of inflammatory mediators released by the immune system. This fundamental action helps to broadly relieve symptoms such as severe swelling, redness, and general tissue irritation that result from many chronic or acute inflammatory and immune system disorders.

Regulatory References

  1. NIH

What side effects are possible with Perazone?

Possible side effects and safety information

Perazone (Dexamethasone) is a potent synthetic corticosteroid, and its documented safety profile is characterized by systemic effects that are often linked to the dose and duration of exposure, as noted in official regulatory documents. Adverse reactions are formally grouped by affected physiological systems, known as System-Organ Classes (SOCs).

Many effects, such as fluid retention, weight gain, and psychiatric disturbances (including mood changes), are classified as Common or Very Common, reflecting the drug’s broad metabolic and endocrine influence. Less frequent, or Rare, adverse reactions include serious events like peptic ulceration and avascular osteonecrosis.

Serious Adverse Reactions and Key Safety Patterns

Official labeling emphasizes several high-consequence adverse reactions. Adrenocortical insufficiency is a serious concern, particularly when treatment is withdrawn abruptly after long-term use. Other serious reactions documented in regulatory text include severe gastrointestinal hemorrhage or perforation, and the increased risk of developing opportunistic infections due to immunosuppression.

Long-term exposure is explicitly linked to the development of chronic conditions, including osteoporosis and the formation of posterior subcapsular cataracts.

Population-Specific Safety Notes

The regulatory profile highlights specific safety considerations for vulnerable patient groups. The pediatric population has a documented risk of growth retardation and developmental suppression of the HPA axis. Older adults are noted to have an increased susceptibility to adverse reactions such as hypertension and bone density loss. Additionally, the medicine is strictly contraindicated in individuals with known systemic fungal infections or a documented hypersensitivity to the active substance or excipients.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Perazone (Dexamethasone) states that acute overdosage is not expected to cause a life-threatening situation. However, severe manifestations are associated with chronic overuse or high-dose exposure.

Documented Manifestations and Severe Outcomes

Exposure to excessive amounts of Dexamethasone may result in signs of excess steroid hormones. These include the development of a Cushingoid state and physiological issues such as fluid and electrolyte disturbances and hyperglycemia. More serious outcomes documented in labeling include convulsions, heart rhythm disturbances, and severe gastrointestinal complications like peptic ulcer with perforation and hemorrhage. Adrenocortical insufficiency may also occur following the abrupt cessation of chronic high-dose use.

Mandated Emergency Action and Treatment

It is mandated that individuals seek immediate medical attention for any suspected overdosage. When symptoms become life-threatening—such as trouble breathing, collapse, or seizure—government guidance requires contacting emergency services or the Poison Help hotline immediately. Treatment for overdosage is symptomatic and supportive therapy only, as no specific antidote is known. Hospital monitoring, including assessment of vital signs, blood tests, and fluid balance, is required to manage the documented physiological effects.

Therapeutic Uses of Perazone

Perazone (Dexamethasone) is considered relevant for its role in providing symptomatic relief and supportive management across several domains characterized by severe, acute, or debilitating immune and inflammatory activity. It is applied in contexts where additional support for symptom management is needed to address pronounced manifestations and supporting patient comfort. Its uses span numerous body systems.


Severe Autoimmune Flares and Generalized Inflammation

This domain covers the medication’s role in managing acute exacerbations of conditions characterized by periods of heightened symptoms, such as Rheumatoid Arthritis or Systemic Lupus Erythematosus. Perazone helps address symptom clusters that may become intense, such as severe, widespread swelling, redness, and debilitating pain in joints or organs, providing support that helps ease the overall symptom burden.


Critical Swelling and Acute Allergic Reactions

Perazone is relevant in clinical settings that involve acute or unstable symptom patterns caused by rapidly escalating symptoms that create noticeable physiological strain. This includes its use to moderate pronounced airway swelling in conditions like severe Asthma exacerbations or Croup, and to assist with managing generalized manifestations of acute hypersensitivity reactions, certain blood disorders, and cerebral edema. The medication may assist with supporting functional stability by providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Support for Pronounced Systemic Swelling


Neurological and Specialized Supportive Care

The medication is applied across domains where additional symptomatic support is needed, particularly to manage symptoms of increased neurological activity linked to pressure, such as cerebral edema associated with brain tumors. It is also commonly used as supportive care in advanced cancer to contribute to easing distress during periods of heightened symptoms.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Perazone (Cefoperazone)

Perazone, which contains the antibiotic Cefoperazone, has specific eligibility criteria defined by regulatory documents to ensure safe use. These criteria govern who is contraindicated from using the medicine and who requires special consideration.

Eligibility Status Applicable Population
Contraindicated Individuals with a known, severe hypersensitivity or allergic reaction history to cefoperazone, any other cephalosporin antibiotic, or any of the product’s excipients.
Special Consideration Patients with hepatic disease (liver disease) or biliary obstruction may require dosage adjustment due to the drug's primary excretion route. Doses should not exceed 2g/day of cefoperazone without close serum monitoring in cases of combined liver and significant kidney impairment.
Generally Allowed Patients with renal impairment typically do not require a specific dose adjustment for cefoperazone alone, but may for combination products. Use in the elderly is generally allowed, but caution is advised due to the higher likelihood of age-related organ compromise.
Pregnancy/Lactation Use during pregnancy and breastfeeding is permitted only when clearly needed and prescribed, as the drug may appear in breast milk, though in low levels.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Perazone (Dexamethasone) is largely defined by its metabolism and its potent effects on various physiological systems, as documented in regulatory information. Interactions are primarily categorized as metabolic clearance alteration and pharmacodynamic reinforcement.

Pharmacokinetic Interactions

Dexamethasone is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with strong CYP3A4 inducers (e.g., Rifampin, Phenytoin) may officially result in a decrease in Dexamethasone plasma concentration. Conversely, strong CYP3A4 inhibitors (e.g., Ketoconazole) are noted to increase Dexamethasone plasma concentration.

Pharmacodynamic and Substance Interactions

Substance Category Documented Interaction Outcome Restriction/Condition
NSAIDs (e.g., Aspirin) Increased risk of gastrointestinal ulceration. Use may require monitoring.
Potassium-Depleting Agents Increased risk of hypokalemia and electrolyte disturbance. Use may require monitoring.
Mifepristone Reduced corticosteroid effect. Co-administration is generally not recommended.
Live Virus Vaccines Reduced immune response (immunosuppressive doses). Contraindicated during immunosuppressive therapy.
St. John’s Wort / Grapefruit Juice Altered Dexamethasone exposure (induction/inhibition). Officially documented modulation.

Use of Perazone is formally contraindicated in the presence of systemic fungal infections. Additionally, official labeling notes that the effect of Dexamethasone may be enhanced in specific populations, such as those with hepatic impairment (cirrhosis), due to decreased metabolic clearance.

Mechanism of Action

Perazone (Cefoperazone) is a beta-lactam molecule that acts by interfering with bacterial cell wall biosynthesis. The agent functions as an acylating inhibitor by targeting Penicillin-Binding Proteins (PBPs), which are transpeptidases essential for the final cross-linking step of peptidoglycan formation. Binding of the beta-lactam ring to the active site of the PBPs irreversibly inactivates the enzyme. This inhibition prevents the formation of cross-links between adjacent peptidoglycan strands, which are required for structural integrity and rigidity. The resulting defect in the cell wall structure prevents the cellular envelope from withstanding internal osmotic pressure. The intracellular cascade leads to the activation of bacterial autolytic enzymes. The ultimate system-level physiological consequence of this mechanistic cascade is the structural disruption and subsequent lysis of the target microorganism. Perazone demonstrates a characteristic affinity for PBPs across a range of microbial species.

Dosage and Administration Information

How to Use Perazone (Sulbactam/Cefoperazone)

Perazone, a combination of sulbactam and cefoperazone, is provided as a sterile dry powder for injection and must be administered by a healthcare professional. The approved routes are intravenous (IV) or intramuscular (IM) injection.

Official Dosing and Frequency

  • Adult Usual Dose: 2 to 4 grams of the combination daily, administered in equally divided doses every 12 hours.
  • Pediatric Dosing: The usual dosage is 40 to 80 mg/kg per day, given in 2 to 4 equally divided doses. For neonates in the first week of life, the drug should be administered every 12 hours.

Preparation and Administration

The powder must be initially reconstituted with an appropriate sterile solvent, such as Sterile Water for Injection or 0.9% Sodium Chloride.

Administration Method Procedural Instruction (Minimum)
IV Injection Administer slowly over a period of at least 3 minutes.
IV Intermittent Infusion Dilute the reconstituted solution further (e.g., to 20 mL or more) and infuse over 15 to 60 minutes.
IM Injection Administer deep into a large muscle mass.

Dose Adjustments

Dosage regimens must be adjusted in patients with significantly reduced kidney function (creatinine clearance < 30 mL/min) to compensate for the reduced clearance of the sulbactam component. For patients receiving hemodialysis, administration should be scheduled to occur after the dialysis procedure. In cases of severe liver disease or coexisting liver and kidney problems, the cefoperazone component should not exceed 2 grams per day without close monitoring of serum concentrations.

Recent Clinical Evidence

Research Evidence for Perazone: Overview of Studies

This overview summarizes the research that has been conducted on the medicine Perazone, whose active compound is Dexamethasone. It focuses on describing the types of studies available, the specific patient outcomes that were measured, and the recognized limits of the evidence base. This information is intended to provide context but does not offer any personal medical advice or recommendations for use.


Evidence for Use in Acute Inflammatory Conditions and Autoimmune Flares

Research includes Randomized Controlled Trials (RCTs) and systematic reviews that have explored the active compound in conditions characterized by fluctuating or episodic manifestations, particularly during phases of heightened symptom activity. The studies have monitored metrics such as changes in formal disease activity scores, patient-reported physical discomfort levels, and formal assessments of metrics for daily functioning. While research highlights measured changes during the study period, the studies often focused on short-term follow-up (ranging from days to one month) to assess the initial patterns of measured change in the heightened symptoms.


Evidence for Use in Critical Swelling and Acute Allergic Reactions

Comparative studies and meta-analyses have investigated the active compound's application in managing rapid-onset, pronounced symptoms, including those studied in asthma exacerbations. The research primarily examined outcomes describing episodic or acute changes, such as the rate of unscheduled return visits to emergency departments or hospital admission frequency. In comparative research, studies monitored and reported on measured differences in symptom resolution and relapse rates when the compound was used versus other corticosteroids. However, certainty remains low for some of these comparative outcomes due to variability in the methodologies and the patient populations included.


Evidence for Use in Neurological and Specialized Supportive Care

In research exploring the active compound in patients with swelling linked to tumors, the evidence base includes high-level RCTs that examined outcomes related to functional imbalance and neurological status in adult patients. Studies monitored the volume of cerebral swelling using imaging and assessed metrics for a patient's functional capacity. For cancer supportive care, studies monitored patients with advanced cancer for outcomes describing perceived discomfort, such as fatigue and appetite changes. Findings were mixed across studies exploring chronic symptom management, with some research reporting measured changes and other trials failing to meet pre-specified activity thresholds for chronic fatigue. This evidence is limited and heterogeneous in its results, particularly for sustained management of non-acute symptoms.

Key Studies & References

  1. Dexamethasone for the management of cancer-related fatigue: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Perazone (FAQ)

Q: What is Perazone used for?

A: Perazone is a prescription medication approved to manage specific conditions, including Type 2 Diabetes Mellitus and certain forms of Chronic Heart Failure. The approved indications are based on clinical data reviewed by regulatory authorities.


Q: How does Perazone work?

A: Perazone is thought to influence certain signaling pathways in the body. Research suggests it acts as an SGLT2 inhibitor. However, the precise way it exerts its clinical effects is the subject of ongoing research.


Q: What are the potential side effects of Perazone?

A: As with any prescription medication, Perazone is associated with potential side effects. The most commonly reported side effects in clinical trials include urinary tract infections, genital yeast infections, and increased urination. A healthcare professional can provide a complete list and discuss individual risk factors.


Q: When will I notice the effects of Perazone?

A: The timeframe for observing a clinical effect from Perazone can vary among individuals. In clinical studies, changes in certain markers may be noted within weeks. Patients should consult their prescribing clinician to set appropriate expectations and discuss monitoring.

How should Perazone be stored and disposed of?

How to Store and Dispose of Perazone (Dexamethasone)

The storage and disposal instructions for Perazone are strictly defined by official regulatory labeling to maintain product stability and safety.

Storage Requirements

The product must be stored at Controlled Room Temperature (20 C to 25 C). It is mandatory to keep the medicine in its original container, which must be tightly closed, and protect it from both light and moisture. Perazone must not be frozen. All forms must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of expired or unused medication should prioritize official medicine take-back programs. If this option is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed bag, and discarded in the household trash. The product must not be thrown into wastewater (flushed down the toilet or poured down a sink) unless explicitly directed by official labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Perazone found in:

A-Z Index: